Feed RNAC
RN

Cartesian Therapeutics, Inc.

RNAC · NASDAQ

$8.08 +0.25% (+$0.02)
1M -19.68%
Market Cap $237.4M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 160.73x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining
Rev. growth 70.66%
Book val. growth N/A
EPS growth N/A
Profitability
0 /100
Weak
Op. margin 6,679.69%
Gross margin 766.42%
FCF margin 5,291.54%
Quality
0 /100
Poor
Asset turnover 0.00x
ROIC 30.78%
ROA 48.31%
Debt
43 /100
Moderate
Int. coverage -188.07x
Current ratio 7.48x
Debt/Assets N/A
Stability
26 /100
Unstable
EPS volatility 1,029.74%
Beta 0.62x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RNAC
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Carsten Brunn

Employees

75

Headquarters

Frederick

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.